We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Proteomic Methods Diagnose Pancreatic Cancer

By LabMedica International staff writers
Posted on 08 Apr 2014
A method has been developed that identifies pancreatic cancer's visible precursors with 97% certainty, and is expected to aid in the early discovery of the cancer as well as minimize the risk of unnecessary surgery. More...


The poor prognosis for pancreatic cancer, is due to the fact that the tumors often develop unnoticed, and rarely causes symptoms until they have spread to other organs, however fluid-filled compartments in the pancreas, called cysts, may be precursors of the cancer.

Scientists at the Sahlgrenska University Hospital (Gothenburg, Sweden) evaluated whether cyst fluid mucin expression could predict malignant potential and/or transformation in pancreatic cystic lesions (PCLs). A proteomic method was devised and prospectively evaluated in consecutive patients referred to a tertiary center for endoscopic ultrasound-guided aspiration of cystic lesions from May 2007 through November 2008 (discovery cohort) and from December 2008 through October 2012 (validation cohort).

Cytology and cyst fluid carcinoembryonic antigen (CEA; premalignancy greater than 192 ng/mL, malignancy greater than 1,000 ng/mL) were routinely analyzed. Samples were further processed as follows: one-dimensional gel electrophoresis, excision of high-mass areas, tryptic digestion and nanoliquid chromatography–tandem mass spectrometry, with peptide identification. Peptides were separated on a reversed column coupled to a hybrid linear ion trap-Fourier transform ion cyclotron resonance mass spectrometry instrument equipped with a 7-tesla magnet (LTQ-FT; Thermo Electron; Bremen, Germany).

Proteomic mucin profiling proved statistically significantly more accurate at 97.5%; than cytology at 71.4%, and cyst fluid CEA at 78.0% in identifying the 37/79 (46.8%) lesions with malignant potential, either premalignant or malignant tumors. The accuracy of proteomics was nearly identical, 96.6% versus 98.0%, between the 29 patients in the discovery and 50 patients in the validation cohorts. Furthermore, mucin profiling predicted malignant transformation, present in 16/29 lesions with available histology, with 89.7% accuracy.

Karolina Sjöberg Jabbar, MD, the corresponding author of the study said, “This is an exceptionally good result for a diagnostic test, and we are very hopeful that the method will enable more instances of early discovery of pancreatic cancer, at a stage when the cancer can be treated or prevented. This approach may also minimize the risk of unnecessary operations on nonmalignant cysts.” The study was published in the March 2014 issue of the Journal of the National Cancer Institute.

Related Links:
Sahlgrenska University Hospital  
Thermo Electron 


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.